Company Overview and News

20
47 'Safer' Dividends From 119 Monthly Paid Canadian Equities For June

2018-06-03 seekingalpha
47 of 119 Monthly Paying (MoPay) Canadian (CAD) Equities were tagged "safer"showing positive annual-returns, and free cash-flow-yield greater than their dividend-yield per market-data gathered 5/29/18. All quotes are $CAD.
TAHO CWYUF CJREF THO CNDCF BK CJR.B CGIFF CRIUF MR.UN

0
119 Monthly Pay Canadian Dividend Stocks Show 1% To 19% Yields To June 2019

2018-06-02 seekingalpha
Monthly Paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
CCAOF EBGUF FFN OSP.PR.A CBL NAF.UN AD ALARF CRIUF BNEFF CHW.DB SOT.UN CJR.B CHW MR.UN AHOTF OSP CNDCF BK CHWWF CGIFF BNE LCS CJREF LCS.PR.A FNCSF

0
Canadian Banc Corp. Completes Overnight Offering of $68,065,250

2018-05-23 globenewswire
TORONTO, May 23, 2018 (GLOBE NEWSWIRE) -- Canadian Banc Corp. (the “Company’) is pleased to announce it has completed the overnight offering of 2,915,000 Preferred Shares and 2,915,000 Class A Shares of the Company. The total proceeds of the offering were $68.1 million, bringing the Company’s net assets to approximately $253.0 million. The shares will trade on the Toronto Stock Exchange under the existing symbols of BK.
CNDCF BK

5
Canadian Banc Corp. Monthly Dividend Declaration for Class A & Preferred Share

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Canadian Banc Corp. (The "Company") declares its monthly distribution of $0.10942 for each Class A share and $0.04167 for each Preferred share. Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
TNTTF CNDCF BK TD TD

0
Canadian Banc Corp. Announces Successful Overnight Offering

2018-05-09 globenewswire
TORONTO, May 09, 2018 (GLOBE NEWSWIRE) -- Canadian Banc Corp. (the “Company’) is pleased to announce it has completed the overnight marketing of up to 2,915,000 Preferred Shares and up to 2,915,000 Class A Shares of the Company. Total proceeds of the offering are expected to be approximately $68.1 million.
CNDCF BK

0
BRIEF-Canadian Banc Announces Overnight Offering Of Its Preferred Shares & Class A Shares

2018-05-08 reuters
* CANADIAN BANC - FILED PRELIMINARY SHORT FORM PROSPECTUS IN EACH OF PROVINCES OF CANADA REGARDING AN OFFERING OF CO’S PREFERRED SHARES & CLASS A SHARES
CNDCF BK

0
Canadian Banc Corp. Announces Overnight Offering

2018-05-08 globenewswire
TORONTO, May 08, 2018 (GLOBE NEWSWIRE) -- Canadian Banc Corp. (the “Company’) is pleased to announce it has filed a preliminary short form prospectus in each of the provinces of Canada with respect to an offering of Preferred Shares and Class A Shares of the Company. The offering will be co-led by National Bank Financial Inc., CIBC World Markets Inc., Scotia Capital Inc. and RBC Capital Markets, and will also include TD Securities Inc.
CNDCF BK

5
Canadian Banc Corp. Monthly Dividend Declaration for Class A & Preferred Share

2018-04-18 globenewswire
TORONTO, April 18, 2018 (GLOBE NEWSWIRE) -- Canadian Banc Corp. (The "Company") declares its monthly distribution of $0.11183 for each Class A share and $0.04167 for each Preferred share. Distributions are payable May 10, 2018 to shareholders on record as at April 30, 2018.
TNTTF CNDCF BK TD TD

20
42 Of 132 Monthly Pay Dividend Canadian Stocks Pay 'Safer' Dividends For April

2018-04-08 seekingalpha
42 of 132 Monthly Paying (MoPay) Canadian (CAD) Equities were tagged "safer" because they showed positive annual-returns, and free cash-flow yield greater than their dividend yield per market data gathered.
TAHO CWYUF CJREF THO CNDCF BK CJR.B ACRVF BTBIF FCMGF MR.UN ACR.UN

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:BK / Canadian Banc Corp on message board site Silicon Investor.

Barnes u0026 Noble (BKS) BANK OF NEW YORK
NetBank(NTBK)-formerly Atlanta Internet Bank Buckeye Cellulose - BKI Low PE- High Growth
CLBK: Commercial Bankshares,Inc CBK - a niche player in womenu0027s fashion
Hudson City Bancorp, Inc. (HCBK) Berkeley Capital (BKLYY)
Peopleu0027s Bancshares, Inc. (u0027PBKBu0027) RCBK: Richmond County Financial